Therefore, TGFβR1 antagonists as new drugs for the treatment of myelodysplastic syndrome, primary hepatocellular carcinoma, glioma, metastatic pancreatic cancer, and other malignant tumors have attracted much attention [5,6]. This evidence concerns the gene TGFBR1 and myelodysplastic syndrome.